Cardiac Arrhythmia
Conditions
Keywords
Electrophysiology, Arrhythmias, Arrhythmia ablation, Ionizing radiation risk, Oxidative stress, DNA damage biomarkers
Brief summary
Catheter ablation procedures (CAPs) are first line treatment for a great variety of cardiac arrhythmias. CAPs require X-Ray imaging; consequently, CAPs cause ionizing radiation (IR) exposure for patients. Exposure to IR, even at low-doses, increases individual risk of developing cancer. IR cause DNA damage directly and, mostly, indirectly by formation of cellular free radicals. Furthermore different response to IR results from inherited variants in genes involved in DNA damage repair. N-acetylcysteine (NAC) is an aminoacid that can directly neutralize free radicals and increase antioxidant systems. Our preliminary data suggest that IR exposure in patients undergoing CAP deranges the oxidative stress status and the pre-procedure intravenous administration of NAC could decrease such abnormality.
Detailed description
CARAPACE is a prospective, randomized, single-blinded, parallel-arm monocenter study. Eligible patients undergoing CAP at the Arrhythmology Unit of Centro Cardiologico Monzino will be enrolled. The hypothesis driving our study, based on published literature and our preliminary data, is that administration of antioxidant agents, before cardiac procedures involving IR exposure, might prevent IR harmful effects on human tissues in terms of reduction of systemic oxidative stress status and, in parallel, of oxidative DNA damage. The antioxidant agent tested in our study is NAC. NAC is a well-tolerated and safe medication and it has antioxidant properties is based on three main mechanisms: 1) direct antioxidant effect, 2) glutathione (GSH) precursor action, and 3) its activity in breaking thiolated proteins. Another hypothesis to be tested is whether genes involved in DNA damage repair could explain the great variability in patient radiosensitivity to IR exposure and whether these genes could affect NAC protective/healing effects.
Interventions
DRUGAcetyl cysteine
1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
Sponsors
Ministry of Health, Italy
Centro Cardiologico Monzino
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Researchers, involved in the assessment of NAC efficacy, are blinded to randomization process; thus, they do not know whether the patients are in the NAC or in the control groups.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient's age \>18 years. * Negative hCG pregnancy test (if appropriate). * Indication to perform CAP guided by fluoroscopy (IR imaging). * Ability and willingness to give informed consent and to comply with protocol.
Exclusion criteria
* Any contraindication to CAP (such as, pregnancy and breastfeeding). * Hypersensitivity to the active substance or to any of the excipients. * Enrollment in another study that may interfere with CARAPACE study. * Administration of an experimental drug within 30 days or 5 half-lives of the investigational drug. * Chronic kidney disease (serum creatinine \>1.5 mg/dl). * Acute/Chronic inflammatory disease. * Antioxidant drugs intake over the previous 2 weeks. * History of radiotherapy or chemotherapy in the last year. * Any documented condition that, in PI's motivated judgement, makes the patient a poor candidate for the study. * Computed tomography and/or coronary angiography within 5 days prior to baseline analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of change in systemic oxidative stress (ratio between GSH oxidized form (GSSG) and GSH, 8-iso-prostaglandinF2α (8-iso-PGF2α) and 8-hydroxy-2-deoxyguanosine (8-OHdG)) and genomic DNA oxidative damage (percentage of DNA present in the tails). | 48 hours | Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails of the comet assay) between the two groups (NAC versus no NAC) at the different time-points (T0 = before CAP, T1 = 3h after CAP, T2 = 24h after CAP, T3 = 48h after CAP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (fluoroscopy time (FT), Dose Area Product (DAP) and effective dose (ED)). | 48 hours | Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) between the two groups (NAC versus no NAC). |
| Measurement of change in genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) and inherited variants in genes involved in DNA damage repair. | 48 hours | Measurement of change in genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) and inherited variants in genes involved in DNA damage repair between the two groups (NAC versus no NAC). |
| Measurement of change in the response to NAC administration related to inherited variants in genes involved in DNA damage repair. | 48 hours | — |
Countries
Italy
Outcome results
None listed